• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

The Weekly Roundup: April 29-May 3


In case you missed it, this week we had news about Dermavant's FDA-accepted sNDA for tapinarof cream 1% for AD, Eli Lilly's resubmitted BLA for lebrikizumab for AD, Rosacea Awareness Month recaps, and more.

Dermatology Times Weekly Roundup logo | Image credit: © Dermatology Times

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

QUIZ: Test Your Knowledge of Rosacea Research and Innovations

Click here to read more and answer our quiz questions in recognition of Rosacea Awareness Month.

FDA Accepts Dermavant’s sNDA for Tapinarof Cream 1% for Adults and Children With AD

The FDA’s PDUFA date is expected in quarter 4 of 2024.

Cosmetic, Psychological Impact of Punch Biopsy in Patients With Tattooed Skin is Minimal

A study found that in addition, recovery time was both quick and yielded minimal symptoms.

Versus Red Light PDT, Patients With Actinic Keratosis Prefer Simulated Daylight PDT

A study revealed that patients with actinic keratosis reported feeling more pain during red light PDT compared to simulated daylight PDT.

Anna López-Ferrer, MD, PhD, and Volker Koscielny, MD, MBA, Share Highlights From Almirall’s 15th Skin Academy

López-Ferrer discussed how to achieve well-being for patients with psoriasis and Koscielny discussed the unique topics of the Skin Academy.

Interview Intersection: Expert Interviews From April 2024

Dermatology Times is recapping our top expert interviews from the month of April.

Eli Lilly Resubmits BLA for Lebrikizumab for the Treatment of Moderate to Severe AD

A decision from the FDA is expected in the second half of 2024.

Dermatology Times April 2024 Recap

Dermatology Times is looking back on the top stories in dermatology from the month of April.

Rosacea Awareness Month Recap

Review Dermatology Times' coverage of Rosacea Awareness Month.

Discovering Dermatology Times: April 2024

Learn more about the in-depth topics covered in the April 2024 print issue of Dermatology Times.

3 Things You Should Know About HS Pathology and Management

Earn CME credit and learn how to optimize a multimodal treatment approach for hidradenitis suppurativa.

Dermatology Conferences and Meetings Calendar 2024: May

Dermatology Times asked our readers to share what conferences they are looking forward to in the second quarter of 2024.

FDA Approves A High-Concentration, Citrate-Free Version of Cyltezo, A Biosimilar to Humira

Adalimumab-adbm is now approved for use in various indications, including psoriasis, psoriatic arthritis, and hidradenitis suppurativa.

Several Barriers Linked to Hindered Access of JAKi Therapy in Patients, Particularly Non-White, With Alopecia Areata

These challenges may exacerbate racial inequities in care access and quality, according to a new study.

Study Is First to Analyze Content and Influence of Fairness Cream Commercials From South Asia

While 84% of commercials targeted female consumers and 77% utilized celebrity influence, less than half mentioned specific ingredients in skin lightening products.

Supporting Patients With AD and Their Caregivers: Insights from Argentina

A recent survey showed education, shared decision-making, and addressing mental health concerns and financial burdens are key priorities in optimizing care.

Skin Cancer Breakthroughs, Prevention, and Treatment Advances During the Past Year

Skin Cancer Breakthroughs, Prevention, and Treatment Advances During the Past Year

ASLAN Expands Collaboration with Zenyaku to Investigate Eblasakimab’s MOA Compared to Other Biologics in AD

The new research will compare eblasakimab to dupilumab and lebrikizumab.

JAK Inhibitors Show Favorable Risk-Benefit Profile In Vitiligo, Especially for Facial Cases

A new review highlighted JAK inhibitors' role in vitiligo treatment, emphasizing varying benefits, facial efficacy, and potential for sustained responses.

Reviewing Concerns For Mental Health and Well-Being in Dermatologic Conditions

May is Mental Health Awareness Month, and Dermatology Times is spotlighting the common relationship between skin conditions and struggles with mental health, quality of life, and well-being.

QUIZ RECAP: Test Your Knowledge of Rosacea Research and Innovations

Earlier this week, we shared our fourth and final Rosacea Awareness Month quiz. Review the answers and your responses below.

Recognizing Melanoma and Skin Cancer Awareness Month

Our May issue of Dermatology Times spotlights melanoma/skin cancer awareness and more.

Alpha Tau to Conduct Trial of Alpha DaRT Technology In Patients With Recurrent Squamous Cell Carcinoma

Robert Den, MD, and Alpha Tau are seeking motivated investigators who may be interested in participating in the trial.

Journal Digest: May 3

This week’s collection of the latest dermatologic studies includes social determinants of health in HS, JNJ-77242113 for moderate to severe plaque psoriasis, sonidegib for locally advanced and metastatic BCC, and pembrolizumab in combination with chemoradiotherapy for locally advanced HNSCC.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.